U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210463) titled 'A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)' on Sept. 29.
Brief Summary: The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological ...